Equity · Healthcare
CCCC
NASDAQC4 Therapeutics (CCCC)
The line runs 3.86 USD on 11 August through 3.08 USD on 6 November, on a scale from 2.5 to 4.5. Days the market did not trade hold the previous close, flat.
- Market cap
- 404.5M USD
- Revenue, year to Dec 2025
- 35.9M USD
- EPS, diluted, year to Dec 2025
- −1.27 USD
- 52-week range
- 1.70 USD – 4.66 USD
- Avg volume
- 216.3K
- Mentions, 30 days
- 1
as of Nov 6, 2026
Have C4 Therapeutics (CCCC) insiders bought or sold shares recently?
In the 90 days to 10 Nov 2026, no C4 Therapeutics insider bought or sold shares on the open market; all 4 Form 4 filings in that window were grants, exercises, tax withholding or transfers (SEC Form 4).
Form 4, 90 days to 10 Nov 2026, newest Form 4 filing 1 Oct 2026
Buys 0Sells 0Other filings 4
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 01 Oct 2026 | Anderson Kenneth CarlDirector | Award | 3,662 | 11K USD |
| 01 Oct 2026 | GROGAN DONNA ROYDirector | Award | 4,618 | 15K USD |
| 18 Sep 2026 | Adams KendraChief Financial Officer | Option exercise | 6,250 | |
| 18 Sep 2026 | Adams KendraChief Financial Officer | Tax withheld | 2,775 | 9K USD |
Which funds hold C4 Therapeutics (CCCC)?
8 of the 45 institutional funds we track reported a C4 Therapeutics position for the quarter ended 30 Jun 2026 — a combined 54.2M USD; the latest of those filings landed 02 Sep 2026.
| Fund | Position | Shares | Value | Shares q/q |
|---|---|---|---|---|
| Citadel Advisors | Added | 4,187,580 | 19.6M USD | +66.8% |
| Two Sigma Investments | Held (±25%) | 3,469,707 | 16.2M USD | +14.3% |
| D. E. Shaw & Co. | Added | 1,740,989 | 8.1M USD | +64.2% |
| Renaissance Technologies | Trimmed | 1,189,828 | 5.6M USD | −51.7% |
| Man Group | Added | 408,648 | 1.9M USD | +59.3% |
| Marshall Wace | Added | 227,003 | 1.1M USD | +46.0% |
| Millennium Management | Trimmed | 215,386 | 1.0M USD | −84.5% |
| Point72 Asset Management | Held (±25%) | 173,965 | 812K USD | +2.9% |
What has been filed or recorded for C4 Therapeutics (CCCC)?
The filings we hold for C4 Therapeutics, newest first: 6 quarterly earnings reports, 2 annual reports and 5 reported financial figures, the latest dated 30 Sep 2026. No next earnings date is announced in SEC filings yet.
| And | ||||
|---|---|---|---|---|
| 30 Sep 2026 | Quarterly earnings | Q3 2026 reported | EPS −0.16 USD | Revenue $8M |
| 30 Sep 2026 | Financials | Total assets | 331.8M USD | at period end |
| 30 Sep 2026 | Financials | Total equity | 228.2M USD | at period end |
| 30 Jun 2026 | Quarterly earnings | Q2 2026 reported | EPS −0.18 USD | Revenue $7M |
| 31 Mar 2026 | Quarterly earnings | Q1 2026 reported | EPS −0.20 USD | Revenue $6M |
| 31 Dec 2025 | Annual report | FY 2025 reported | EPS −1.27 USD | Revenue $36M |
| 31 Dec 2025 | Financials | Revenue | 35.9M USD | fiscal year |
| 31 Dec 2025 | Financials | Net income | −105.0M USD | fiscal year |
| 31 Dec 2025 | Financials | Diluted EPS | −1.27 USD | fiscal year |
| 30 Sep 2025 | Quarterly earnings | Q3 2025 reported | EPS −0.44 USD | Revenue $11M |
| 30 Jun 2025 | Quarterly earnings | Q2 2025 reported | EPS −0.37 USD | Revenue $6M |
| 31 Mar 2025 | Quarterly earnings | Q1 2025 reported | EPS −0.37 USD | Revenue $7M |
| 31 Dec 2024 | Annual report | FY 2024 reported | EPS −1.52 USD | Revenue $36M |
What is Reddit saying about C4 Therapeutics (CCCC)?
Reddit mentioned CCCC 1 times in the 30 days to 9 November 2026, in 1 of the communities we track. All of them were scored for sentiment: 100% read bullish, 0% bearish and 0% neither. Reddit data updated 9 November 2026.
30-day window, Method
Mentions, 30 days 1Communities 1
How do Reddit mentions of C4 Therapeutics (CCCC) compare with its price?
Share ↗
Where C4 Therapeutics (CCCC) is discussed
30 days
| Community | Share | Mentions | Net sentiment |
|---|---|---|---|
| r/wallstreetbets | 100% | 1 | +0.08 |
C4 Therapeutics (CCCC): frequently asked questions
What did C4 Therapeutics shares close at?
C4 Therapeutics closed at 3.08 USD on 6 Nov 2026, up 4.05% on the close before. That is the end-of-day price from Finazon, not a live quote.
What is C4 Therapeutics’ market cap?
C4 Therapeutics is worth 404.5M USD by market value as of 6 Nov 2026, which is the share price times the shares on issue from its SEC filings.
What is C4 Therapeutics’ revenue?
C4 Therapeutics reported revenue of 35.9M USD for the year ended 31 Dec 2025, as filed with the SEC. See Filings
Have C4 Therapeutics insiders bought or sold shares recently?
In the 90 days to 10 Nov 2026, no C4 Therapeutics insider bought or sold shares on the open market; all 4 Form 4 filings in that window were grants, exercises, tax withholding or transfers (SEC Form 4). See Insiders
Which funds own C4 Therapeutics?
8 of the 45 funds we track reported a C4 Therapeutics position for the quarter ended 30 Jun 2026, per their SEC Form 13F filings. The largest reported positions were Citadel Advisors, Two Sigma Investments and D. E. Shaw & Co. See Funds
When did C4 Therapeutics last report earnings?
C4 Therapeutics last reported earnings on 30 Sep 2026 for Q3 2026, with EPS of −0.16 USD; no next date is announced in SEC filings yet. See Filings
What is Reddit saying about C4 Therapeutics?
C4 Therapeutics was mentioned 1 times in the last 7 days across the finance subreddits we track, and 1 times over the trailing 30 days. Of the 1 mentions scored for sentiment, 100% read bullish and 0% bearish. That is a social signal, not investment advice. See Reddit
Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.
References
- Finazonprior-day close, indicative (IEX-derived, not the official close), some closes dollar-rounded at the source
- TradingViewthe price chart widget, drawn by TradingView from their own data
- RedditReddit ingest across the tracked finance subreddits
- SEC EDGARForm 4 filings (insider transactions)
- SEC EDGAR13F filings
- SEC EDGARXBRL company facts, latest period ended 30 Sep 2026
- SEC EDGARreported earnings figures and scheduled report dates
- SEC EDGARValuation computed from SEC EDGAR filings